Results of a Phase 1/2a dose–escalation study of FF-10501-01, an IMPDH inhibitor, in patients with acute myeloid leukemia or myelodysplastic syndromes

Authors :: Hetty E. Carraway
Aaron T. Gerds
Hagop M. Kantarjian
Michael R. Kurman
Farhad Ravandi
Ricardo De Lumpa
Mary Johansen
Sudipto Mukherjee
Mikkael A. Sekeres
Hiroyuki Iwamura
Yesid Alvarado
Naveen Pemmaraju
Anjali S. Advani
Elias Jabbour
Guillermo Garcia-Manero
Linda Bavisotto
Motohiko Murase
Aziz Nazha
Kiran Naqvi
Gary Maier
Source :: Leukemia & Lymphoma. 61:1943-1953
Publication Year :: 2020
Publisher :: Informa UK Limited, 2020.
Abstract: FF-10501-01 potently inhibits inosine-5-monophosphate dehydrogenase (IMPDH), inducing anti-proliferative and pro-apoptotic effects in acute myeloid leukemia (AML) human cell lines resistant to hypomethylating agents. In this Phase 1/2a study, Phase 1 enrolled 38 patients with relapsed/refractory AML (

Full Text Access

Tools